GERRESHEIMER AG
Commented by Fabian Lorenz on July 13th, 2026 | 07:40 CEST
Time to Exit Gerresheimer? TKMS Earns a Buy Rating as HPQ Silicon Attracts Growing Interest
Should investors sell shares of Gerresheimer? That is what some analysts are now recommending. Yet, following accounting issues, the delayed release of the annual report, speculation surrounding the BaFin audit, and changes in the executive board, things had recently settled down somewhat at the packaging specialist for the pharmaceutical and cosmetics industries. The stock had even staged a solid recovery. HPQ Silicon, meanwhile, could be poised for a revaluation. The technology company is entering the commercialization phase with several products, and its latest positive results have significantly increased interest from potential industry partners. Strategic options include joint ventures, licensing agreements, royalty-based production partnerships, and in-house production facilities. Against this backdrop, the stock appears to offer further upside potential. The same may be true for thyssenkrupp Marine Systems (TKMS). Following its recent multi-billion-dollar contract from Canada, analysts have raised both their earnings estimates and price targets. The order is expected to secure the company's production backlog well into the 2040s.
Read
Commented by Carsten Mainitz on June 19th, 2026 | 07:15 CEST
These Stocks Deliver Shareholder Value: RE Royalties and Allianz Leading the Way—Gerresheimer Catching Up?
The concept of shareholder value is widely recognized in the capital markets. It refers to the value a company creates for its shareholders, with the goal of maximizing that value. Strategic decisions, investments, and acquisitions are made with this principle in mind. Success can be gauged by stock price increases, dividends, and share buybacks, and measured by metrics such as earnings growth, return on equity, and free cash flow. A long-term approach takes precedence over short-term, quarterly thinking. Following an announcement this spring, RE Royalties is consistently pursuing a path to create shareholder value, and the stock has already responded positively. Nevertheless, there is still room for growth. Allianz also stands out as a good allocator of capital. Gerresheimer, on the other hand, has clearly failed in its plans to increase shareholder value over the past two to three years. However, with the entry of activist investors, the picture could soon change. What should investors keep in mind?
Read
Commented by Fabian Lorenz on March 6th, 2026 | 07:20 CET
SHORT SQUEEZE at Gerresheimer? Will Bayer and MustGrow soon grow together?
While the stock market digests the Iran war and rising energy prices, Gerresheimer's share price is suddenly rising noticeably. There is no news. Is a short squeeze possible? Short sellers had even expanded their positions recently. Bayer does not (yet) hold a stake in MustGrow. However, the Leverkusen-based company has acquired a license to distribute the innovative agricultural products and is investing in their approval. This could enable MustGrow shares to make the leap from hidden gem to high flyer. Management has recently expressed optimism. The stock appears to be undervalued. After the sharp setback in recent weeks, analysts see upside potential for Bayer again. However, shareholders should not expect much in terms of revenue and profit growth in the current year. Cash flow is even expected to be significantly negative.
Read
Commented by Fabian Lorenz on February 27th, 2026 | 07:05 CET
Price explosion and price alert! Gerresheimer, Nordex, and AI profiteer American Atomics!
Price explosion at Nordex. After strong quarterly figures, the share price shot up by around 17% in a single day. The company is riding a wave of success, and its order backlog indicates that this trend will continue. Even if the share is no longer a bargain. American Atomics shares are still waiting for a price explosion. The company is active in a market that will make a comeback in the coming decades: uranium. The AI boom is leading to the construction of countless new nuclear power plants. This has also been evident recently in India. Virtually all the major US AI players were present at the India AI Impact Summit. More than USD 250 billion is to be invested in AI infrastructure. Nuclear power capacity is set to increase more than tenfold to 100 GW. American Atomics also plans to benefit from this. At Gerresheimer, on the other hand, the crash continues. After analysts slashed the price target, BaFin also expanded its investigations. Investors are shocked.
Read
Commented by Armin Schulz on February 20th, 2026 | 07:20 CET
Commodity rush at Almonty Industries, sell-off at SAP and Gerresheimer – where it is worth getting in now
Three companies, two setbacks – and one strategic opportunity. While Almonty Industries is successfully ramping up its tungsten project in South Korea and positioning itself as a Western commodity pillar, SAP and Gerresheimer have recently experienced difficult stock market phases. The cloud company fell well short of its quarterly targets and lost 17%, while the pharmaceutical equipment supplier is struggling with its third consecutive decline in revenue despite booming GLP-1 therapies. Almonty, SAP, and Gerresheimer are prime examples of how different strategic importance and market volatility can be at present. We analyze the current situations.
Read
Commented by Carsten Mainitz on February 12th, 2026 | 07:55 CET
Watch out! Gerresheimer slumps 30%, NEO Battery Materials as a game changer, Schott Pharma surprises positively
Many stories of success and failure are written on the stock market. NEO Battery Materials, the game changer in battery technology, is particularly exciting. The Canadian company offers manufacturers of drones, robots, and electric vehicles customizable high-performance batteries produced in the West. With its innovative approach, the company is setting new standards in terms of performance, charging speed, and price, thereby addressing a huge market that experts estimate will grow to around USD 30 billion by 2032. The examples of Gerresheimer and Schott Pharma show how differently companies in the same industry can develop: Schott exceeded market expectations in the first quarter, while Gerresheimer shocked the markets once again.
Read
Commented by Fabian Lorenz on December 29th, 2025 | 07:00 CET
Comeback 2026! Tenfold potential? Evotec, Gerresheimer, and Desert Gold shares!
Looking for a potential ten-bagger in the gold sector? Analysts believe this could be possible for Desert Gold. The recently published PEA for the flagship gold project is triggering new price speculation. This could finally end the years-long sideways trend and allow the stock to take off. Investors had hoped for a turnaround in 2025 at Evotec. Instead, the biotech stock continued its downward trend. The strategy of the new management team does not appear to have convinced major shareholders either. Gerresheimer was an unpleasant surprise in 2025. At the turn of the year, the Company is at least engaged in damage control. But how significant is the loss of confidence?
Read
Commented by Fabian Lorenz on December 12th, 2025 | 06:55 CET
Buy these stocks now?! Bayer, Gerresheimer, WashTec!
Bayer is undoubtedly one of the positive surprises of 2025 on the German stock market. Operations are running smoothly for the Leverkusen-based company, particularly in the pharmaceutical sector. And next year, the glyphosate disaster could also come to an end. Analysts have now raised their price target. WashTec shares are still at the beginning of an upward trend. Growth, improved margins, a dividend yield of 5%, and a share buyback program continue to argue in favor of buying the stock. Analysts share this opinion. Experts do not yet see the time as right to buy Gerresheimer shares. Although the stock appears to have bottomed out, investors are still advised to wait.
Read
Commented by André Will-Laudien on December 3rd, 2025 | 07:30 CET
Gold, drones, and specialty glass! Just like that, 200% gains out of nowhere with DroneShield, AJN Resources, and Gerresheimer
The stock market is showing its volatile side. While AI, defense, and tech stocks are consolidating, gold and silver are skyrocketing. Sector rotation is therefore in full swing at the end of the year. It is time to take a closer look at some notable movements, because every bull and bear market contains the seeds of the next reversal. DroneShield up 1,000% and then down 75%, AJN Resources suddenly up 200% from a standing start, and Gerresheimer, a fallen angel down 60%, a battered member of the German SME sector. We take a closer look at these stocks – where is it worth taking action?
Read
Commented by André Will-Laudien on November 13th, 2025 | 07:20 CET
Record stock market! And the momentum continues with Palantir, D-Wave, Gerresheimer, and NetraMark
Artificial intelligence (AI) is fundamentally changing drug development by analyzing vast amounts of data in record time and controlling clinical trials more precisely. Advanced systems identify promising drug candidates and predict therapeutic success with impressive accuracy. Companies such as NetraMark are already successfully using these technologies to accelerate development processes. At the same time, the well-known AI stars Palantir and D-Wave are driving the next wave of innovation as pacemakers in data analysis and quantum computing, recording extraordinary share price gains. The German Gerresheimer Group is also increasingly integrating AI-supported solutions into the manufacture of pharmaceutical packaging and medical technology. For investors, this represents a pool of opportunities, but the choice remains difficult!
Read